Investment Thesis
DEXCOM demonstrates exceptional operational execution with robust free cash flow generation ($449M on $1.2B revenue), industry-leading margins (62.9% gross, 21.4% operating), and a fortress balance sheet with minimal debt. The company's 15.6% revenue growth combined with 47.2% EPS growth shows strong operational leverage and pricing power in a high-margin business.
Strengths
- Exceptional free cash flow generation with 37.7% FCF margin, converting profitability into cash at elite levels
- Industry-leading profitability across all levels: 62.9% gross margin, 21.4% operating margin, 16.7% net margin
- Fortress balance sheet with only $2.9M long-term debt, $1.1B cash, 1.95x current ratio, and virtually zero leverage (0.00x debt/equity)
Risks
- Modest return on equity (6.7%) and return on assets (3.0%) indicate potential capital deployment inefficiencies or asset over-capitalization
- Competitive pressures in continuous glucose monitoring market from larger diversified medical device companies
- Regulatory and reimbursement risks inherent in medical device sector; dependence on healthcare policy and insurance coverage decisions
Key Metrics to Watch
- Free cash flow sustainability and growth trajectory
- Gross margin stability amid competitive dynamics
- Return on equity and asset efficiency improvement
- Operating margin consistency at 21%+ levels
- Revenue growth deceleration risks in core CGM market
Financial Metrics
Revenue
1.2B
Net Income
199.5M
EPS (Diluted)
$0.51
Free Cash Flow
449.0M
Total Assets
6.6B
Cash
1.1B
Profitability Ratios
Gross Margin
62.9%
Operating Margin
21.4%
Net Margin
16.7%
ROE
6.7%
ROA
3.0%
FCF Margin
37.7%
Balance Sheet & Liquidity
Current Ratio
1.95x
Quick Ratio
1.64x
Debt/Equity
0.00x
Debt/Assets
55.4%
Interest Coverage
121.57x
Long-term Debt
2.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T17:29:07.783064 |
Data as of: 2026-03-31 |
Powered by Claude AI